The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC
Status:
Recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, single-arm clinical trial, with the purpose to evaluate the therapeutic
efficacy and safety of PD-1 Blockade camrelizumab combined with induction chemotherapy
followed by concurrent chemoradiotherapy and as adjuvant monotherapy in patients with locally
advanced head and neck squamous cell carcinoma.